EP Patent

EP3463416A1 — Methods for diagnosing and treating systemic lupus erythematosus

Assigned to Abcentra LLC · Expires 2019-04-10 · 7y expired

What this patent protects

Described herein are peptides and antibodies for prevention and/or therapeutic treatment of mammals, including humans, against systemic lupus erythematosus, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing SLE and/or…

USPTO Abstract

Described herein are peptides and antibodies for prevention and/or therapeutic treatment of mammals, including humans, against systemic lupus erythematosus, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing SLE and/or to disease grading, staging, and/or prognosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP3463416A1
Jurisdiction
EP
Classification
—
Expires
2019-04-10
Drug substance claim
No
Drug product claim
No
Assignee
Abcentra LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.